ECCO 2022

Is the continuation of combination therapy the key to success in CD?

Combination trials open a new door in IBD treatment

Light at the end of the Pouchitis track

The potential of histology in Crohn´s disease and how AI will contribute

Combined endpoints as new therapy goals

Microbiota manipulation: Still a lot to learn

The first combination therapy trial

Combination with different classes of drugs in moderate to severe UC

SPARE study in ECCO 2022

FMT in UC - still far away from the success story

Proactive TDM

Combination of biologics - finally arrived in IBD!?

Will we improve the management of IBD by combining biologics?

A negative control trial for FMT in UC

Ustekinumab for fistulizing disease

How to deescalate treatment in CD?

Is the speedity of the steroid tapering important during initiation of infliximab?

The interleukin-17 conundrum

Proactive TDM or SOC for monitoring infliximab treatment in immun-mediated patients?

Infliximab withdrawl leeds to a higher risk of (reversible) relapse in Crohn's disease

Filgotinib for fistulizing disease

When to withdraw therapy in crohn's disease?

Combination of biologics

Is stopping of therapy an option in CD?

A new opportunity for proactive TDM disease control

Withdrawal of infliximab or anti-metabolite therapy in CD in sustained remission

FMT is not a promising option for UC patients

Un essai négatif sur la transplantation de microbiote dans la RCH

Kombination von Biologika - endlich bei IBD angekommen!?

Προληπτική μέτρηση των θεραπευτικών επιπέδων του φαρμάκου (TDM) ή κλασική παρακολούθηση της θεραπείας με infliximab σε ασθενείς με ανοσιακά νοσήματα

Das Interleukin-17 Rätsel

Wann Beendigung von Infliximab oder Immunmodulatoren bei M. Crohn?

Du nouveau sur l’allégement thérapeutique au cours de la maladie de Crohn

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την αποτελεσματικότητα της θεραπείας με infliximab

Combinazione di biologici

FMT ist kein vielversprechender Ansatz für UC-Patienten

Il primo trial di terapia biologica di combinazione

מחקר SPARE ב ECCO 2022

FMT w colitis ulcerosa - wciąż daleko od sukcesu

Allons nous améliorer la prise en charge des MICI en combinant les traitements biologiques?

Una nuova opportunità per i TDM nel controllo proattivo di malattia

Ist der Therapiestopp eine Option in CD?

COVID-19: still a moving target!

Inflammatory bowel disease and cancer risk

Can we translate rheumatoid arthritis to ulcerative colitis?

Is combination therapy safe?

Which IBD patients have a higher risk of safety concerns?

A touch of the near future in IBD treatment

The heart is apparently safe with continuous Ozanimod treatment

Breastmilk is tuning IBD risk

Uno sguardo al prossimo futuro nel trattamento delle IBD

Il cuore sembra essere apparentemente al sicuro durante il trattamento continuativo con ozanimod

Muttermilch beeinflusst das IBD-Risiko

Fistulizing Crohn‘s disease - new treatment options with JAKis and IL-12/IL-23 inhibition

The race is on IL-23 – exciting data for CD and UC

Vedolizumab: promising data for pouchitis and IBD in children

Mucosal healing: Will efficacy data translate into real world?

Efficacy update on JAKis

Upadacitinib - will it be the game changer in UC?

Anti-IL-23 - a turning point?

JAK inhibition

Vedolizumab in chronic pouchitis - a new chapter in therapeutic algorithms?

New ways of treatment

Vedolizumab is effective in chronic pouchitis after IPAA for UC

Selective IL-23 blockade

Guselkumab as maintenace treatment in Crohn's Disease

New opportunity in pouchitis treatment

Great news on pouchitis treatment - vedolizumab effective

Nuevos caminos en el tratamiento

JAK-Inhibition

Guselkumab come terapia di mantenimento

Selektive IL-23 Blockade

Una nuova opportunità nel trattamemto della pouchite

Upadacitinib - nowy lek, duże nadzieje

Anti-IL-23 - eine Zeitenwende?

Wedolizumab w pouchitis - początek nowego rozdziału w terapii?

New therapeutic goals in UC

Patient relevant outcomes also show efficacy of upadacitinib in UC

New therapy goals: urgency and disease clearance

Histological findings in mirikizumab treatment

Disease control is possible!

New goals for IBD

Natural history of anal ulcerations in pediatric-onset CD

Disease Control ist möglich!

Nuevas objetivos en las EII

Histoire naturelle de la maladie de Crohn ano-périnéale pédiatrique

Urgency und Disease Clearance

COVID-19 in patients with IBD stratified acc. to therapy

The efficacy of COVID-19 vaccines in IBD - what's new?

תגובה חיסונית לחיסונים כנגד קורונה בחולים עם מחלות מעי דלקתיות מרובדים לפי טיפול

Skuteczność szczepień przeciw COVID-19 w IBD - nowe dane

Ultrasound as a predictor of treatment response

Point of Care Testing / AI / Telemedicine

Ultraschall als Prädiktor des Therapieansprechens

Digitale Tools, KI und Telemedizin

Spanish women leading contribution to ECCO 2022

ECCO guidelines on pregnancy

Las mujeres lideran la contribución española a la ECCO 2022

ECCO Richtlijnen zwangerschap